Hepatic Encephalopathy Management

Introduction to Lactulose Therapy

• The American Association for the Study of Liver Diseases and the European Association for the Study of the Liver recommend lactulose administration at 25-45 mL (20-30g) orally 3-4 times daily, titrated to achieve 2-3 soft bowel movements per day, for the management of hepatic encephalopathy, with improvement expected within 24-48 hours 1, 2, 3, 4
• Long-term lactulose therapy is indicated to prevent recurrence of hepatic encephalopathy, with the European Association for the Study of the Liver suggesting that lactulose works through multiple mechanisms, including lowering colonic pH and altering gut microbiota composition 1, 2, 3

Dosage and Administration

• The recommended adult dosage of lactulose is 2-3 tablespoonfuls (30-45 mL, containing 20-30g of lactulose) 3-4 times daily, with pediatric dosage ranging from 2.5-10 mL in divided doses for infants to 40-90 mL total daily dose for older children and adolescents, as supported by the American Association for the Study of Liver Diseases 1, 2, 3, 4
• Lactulose should be administered orally, with rectal administration reserved for impending or established coma, using 300 mL of lactulose mixed with 700 mL of water or physiologic saline, retained for 30-60 minutes via rectal balloon catheter, as recommended by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases 1, 2, 3

Monitoring and Potential Complications

• Patients on lactulose therapy should be monitored for dehydration, electrolyte disturbances, hypernatremia, and severe perianal skin irritation due to frequent bowel movements, as well as paradoxical worsening of encephalopathy due to overuse of lactulose, with nearly 90% of HE patients able to be treated by correcting precipitating factors alone 1, 2, 3, 4
• The titration goal for lactulose is 2-3 soft bowel movements daily, with monitoring for signs of dehydration, electrolyte disturbances, and clinical improvement in mental status within 24-48 hours, as supported by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 4, 1, 2, 3

Combination Therapy and Special Populations

• Rifaximin 550 mg orally twice daily may be added after a second episode of overt HE within 6 months, although no solid data support the use of rifaximin alone, as recommended by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases 1, 2, 3
• The following table summarizes the outcomes of interventions in specific populations:

• Nutritional considerations include avoiding long-term protein restriction, recommending protein intake of 1.2-1.5 g/kg/day, and considering vegetable and dairy protein sources for patients with recurrent/persistent HE, as supported by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases 2, 3
• Liver transplantation should be considered for patients with recurrent or persistent HE not responding to medical treatment and for patients after their first episode of overt HE, as recommended by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases 4, 1, 2, 3

Additional Therapies

• Branched-chain amino acids (BCAA) may be considered for patients not responding to lactulose and rifaximin at a dosage of 0.25 g/kg/day orally, as suggested by the American Association for the Study of Liver Diseases 2
• L-ornithine L-aspartate (LOLA) may be effective for patients with West-Haven criteria grade 1-2 HE at a dosage of 30 g/day intravenously 2
• Rapid removal of blood from the GI tract using lactulose significantly reduces the incidence of HE (14% vs. 40%), and rifaximin can be considered for HE prophylaxis prior to non-urgent TIPS placement, with smaller diameter covered stents (6-7 mm vs. >8 mm) may reduce post-TIPS HE risk (27% vs. 54%) 3